Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine −

Seegnal Inc. Announces Non-Brokered Private Placement

Seegnal Raises $1.3M at a Discount to Fund Burn Rate as Filing Delays and Going Concern Risks Mount

By The Northwire Desk — AI Analysis Jun 02, 2026 · 17:00 SEGN · 0.35 Seegnal Inc.
Executive Summary
  • Seegnal Inc. announced a non-brokered private placement of up to 4,642,857 units at $0.28 per unit, targeting gross proceeds of up to CDN$1,300,000.
  • Each unit includes one common share and one common share purchase warrant exercisable at CDN$0.50 per share for a 36-month period.
  • Proceeds are designated for general corporate and working capital purposes.
  • Closing is expected in tranches on or before June 30, 2026, subject to TSX Venture Exchange and regulatory approvals.
  • Insiders are expected to subscribe, triggering a related party transaction exemption under MI 61-101.
  • A statutory hold period of four months and one day applies to all issued securities.
  • Finders' compensation may reach 8% of gross proceeds or non-transferable warrants exercisable at $0.50 for 12 months.
Material Impact
  • The financing is dilutive, issued at a 20% discount to the current market price of $0.35. This discount signals management's urgency to secure liquidity but immediately pressures the stock.
  • The capital raise addresses immediate cash flow needs but underscores the company's reliance on equity markets to fund operations, consistent with its negative working capital and going concern status.
  • The placement coincides with a regulatory overhang: the company missed its April 30, 2026 deadline for 2025 annual financial statements and applied for a Management Cease Trade Order (MCTO). While trading for the general public continues, the MTO restricts insider trading and equity issuances, complicating the closing timeline.
  • The U.S. pilot LOI announced on May 19, 2026, is a positive commercial development but remains non-binding and early-stage. It does not offset the immediate financial and regulatory headwinds.
  • Overall, the news is routine for a pre-profit med-tech but carries negative materiality due to the discount pricing, dilution, and persistent reporting delays.
SEGN · Price
Company Overview
  • Seegnal Inc. is an Israeli-based health technology company developing a SaaS clinical decision support platform.
  • Flagship product: The Prescription Intelligence Platform, which analyzes prescription data to identify medication-related risks, optimize therapies, and reduce adverse events.
  • The platform processes over 400,000 prescriptions daily and is deployed across multiple departments in Tel Aviv Sourasky Medical Center.
  • Recent operational milestones include the launch of the "MetricsGuard" module for patient-specific risk detection and the acquisition of the Gold Mark certification from the Standards Institution of Israel, alongside ISO 13485, ISO 27799, and ISO 27001 certifications.
  • Management transitioned to a new CEO, Elad Bibi-Aviv, in December 2025, who has refocused the company on Israel and the U.S. markets while discontinuing non-core initiatives.
Read the original news release →

More from Seegnal Inc.

Jun 25, 2026 · 08:30

Israeli med-tech SaaS expands domestic footprint while navigating severe liquidity constraints and unproven U.S. commercialization.

Other Jun 19, 2026 · 08:30

Seegnal Successfully Initiates First U.S. Pilot Program

Production / Operations Jun 05, 2026 · 08:30

Seegnal Inc. - AI-Driven Prescription Intelligence Platform for Medication Safety

M&A / Property May 19, 2026 · 08:30

Seegnal Eyes U.S. Expansion Amid Regulatory Filing Overhang

Other May 06, 2026 · 17:00

Filing Default Lingers as Seegnal Pushes Audit Deadline

Regulatory Apr 30, 2026 · 23:41

Seegnal to miss April 30 financial filing deadline

Regulatory